Leerink reiterates Abbott Labs stock rating at Market Perform By Investing.com

Abbott Labs reported Q1 2026 adjusted EPS of $1.15 and revenue of $11.16 billion, both roughly in line to slightly above expectations, but lowered full-year adjusted EPS guidance to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition. Leerink Partners reiterated a Market Perform rating with a $119 target, while noting softness in U.S. medical technology, especially diabetes. Shares fell to $95.03 from $100.42 and remain near the 52-week low of $99.05.

Analysis

ABT is starting to look like a classic “good company, bad setup” tape: the near-term issue is not the franchise, but that the market is repricing the quality of its growth algorithm after another step-down in earnings power. The key second-order effect is that lower U.S. med-tech growth in higher-visibility categories will likely pull multiples across the large-cap diversified med-tech group, even for names with better execution, because investors tend to extrapolate category weakness before they differentiate by business mix.

The Exact Sciences dilution matters less for the next quarter than for the next 6-12 months, because it raises the burden of proof on integration synergies while simultaneously reducing room for operating leverage elsewhere. If management cannot show a clean revenue bridge and accretion cadence, the stock may stay in a valuation reset zone despite being defensively positioned on paper. That also creates a relative opportunity: the market may be punishing Abbott for acquisition timing, while competitors with cleaner organic growth can screen better even without better fundamentals.

The contrarian read is that the move may be overstated if the diabetes softness is transitory and if international med-tech momentum is more durable than the U.S. miss implies. In other words, the market is likely pricing a structural deceleration when the evidence so far is more consistent with a mix shift and guidance conservatism. The risk, however, is that this becomes a multi-quarter sentiment drag if two successive updates fail to show reacceleration in the U.S. med-tech core.

From a trading perspective, this is better expressed as relative value than outright conviction: the downside from here is more about time and multiple compression than a fundamental collapse. That makes it attractive for pair trades against higher-quality, faster-growing med-tech peers, while outright longs should wait for evidence that the lowered EPS guide is truly a one-time reset rather than the start of a longer de-rating.

Key Decisions for Investors

• Go long ABT only on weakness with a 3-6 month horizon; use a staggered entry near the 52-week low area and size modestly, because the setup is more valuation-supportive than catalyst-rich.
• Pair trade: long a cleaner organic growth med-tech peer basket vs short ABT for the next 1-2 quarters; the thesis is multiple divergence as investors reward growth visibility and penalize integration risk.
• Avoid adding to ABT into the next earnings cycle unless management gives explicit quantitative detail on Exact Sciences synergies and accretion timing; absence of that roadmap is a near-term overhang.
• For tactical downside hedging, buy short-dated puts or put spreads on ABT around the next investor update if the stock bounces into resistance, since the market is likely to fade relief rallies until guidance credibility improves.